Astrazeneca (AZN) Operating Expenses (2009 - 2026)

Astrazeneca has reported Operating Expenses for 18 years, with the latest figure at -$9.7 billion in Q2 2026.

• On a quarterly basis, Operating Expenses fell 15.36% year-over-year to -$9.7 billion in Q2 2026; TTM through Jun 2026 was -$61.0 billion, a 77.37% decrease from a year earlier, with the FY2025 full-year figure at -$34.2 billion, down 1.8% from the prior year.
• Operating Expenses was -$9.7 billion for Q2 2026 at Astrazeneca, down from -$8.4 billion in the prior quarter.
• The five-year high for Operating Expenses was -$6.7 billion in Q1 2023, with the low at -$34.2 billion in Q4 2025.
• Average Operating Expenses over 5 years is -$9.4 billion, with a median of -$7.8 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses advanced 12.53% in 2022, then plunged 238.7% in 2025.
• Over 5 years, Operating Expenses stood at -$7.2 billion in 2022, then declined by 16.53% to -$8.4 billion in 2023, then decreased by 19.46% to -$10.1 billion in 2024, then slumped by 238.7% to -$34.2 billion in 2025, then surged by 71.6% to -$9.7 billion in 2026.
• The last three Operating Expenses figures came in at -$9.7 billion (Q2 2026), -$8.4 billion (Q1 2026), and -$34.2 billion (Q4 2025), per Business Quant data.